- Home
- GTEC vs IGC Comparison
GTEC vs IGC Comparison
Compare GTEC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTEC
- IGC
- Stock Information
- Founded
- GTEC 2006
- IGC 2005
- Country
- GTEC United States
- IGC United States
- Employees
- GTEC N/A
- IGC N/A
- Industry
- GTEC Industrial Machinery/Components
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- GTEC Industrials
- IGC Health Care
- Exchange
- GTEC Nasdaq
- IGC Nasdaq
- Market Cap
- GTEC 32.2M
- IGC 29.4M
- IPO Year
- GTEC N/A
- IGC N/A
- Fundamental
- Price
- GTEC $1.95
- IGC $0.31
- Analyst Decision
- GTEC
- IGC Strong Buy
- Analyst Count
- GTEC 0
- IGC 2
- Target Price
- GTEC N/A
- IGC $3.75
- AVG Volume (30 Days)
- GTEC 267.2K
- IGC 390.0K
- Earning Date
- GTEC 04-15-2025
- IGC 02-25-2025
- Dividend Yield
- GTEC N/A
- IGC N/A
- EPS Growth
- GTEC N/A
- IGC N/A
- EPS
- GTEC N/A
- IGC N/A
- Revenue
- GTEC $87,352,614.00
- IGC $1,236,000.00
- Revenue This Year
- GTEC N/A
- IGC N/A
- Revenue Next Year
- GTEC $1.70
- IGC $13.38
- P/E Ratio
- GTEC N/A
- IGC N/A
- Revenue Growth
- GTEC 0.76
- IGC N/A
- 52 Week Low
- GTEC $1.36
- IGC $0.27
- 52 Week High
- GTEC $3.69
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- GTEC 37.89
- IGC 42.69
- Support Level
- GTEC $2.20
- IGC $0.29
- Resistance Level
- GTEC $2.54
- IGC $0.33
- Average True Range (ATR)
- GTEC 0.21
- IGC 0.01
- MACD
- GTEC -0.05
- IGC 0.00
- Stochastic Oscillator
- GTEC 0.00
- IGC 43.20
About GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of innovative and quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.